Supernus soars on Indivior merger, Q2 revenue beat
03/08/2026 12:39
BUZZ-Supernus soars on Indivior merger, Q2 revenue beat ** Supernus Pharmaceuticals' shares SUPN.O rise 16.5% to $52 premarket
** Co to merge with Indivior Pharmaceuticals INDV.O to create a diversified biopharmaceutical company specialized in the central nervous system
** INDV stockholders to receive one-time special cash dividend of $1.0 billion in aggregate before the deal closes; SUPN shareholders to receive 1.5401 shares of INDV per SUPN share
** New entity will be named Supernus and current CEO of SUPN, Jack Khattar will lead it
** Deal expected to close in Q4 of 2026
** Co posts Q2 revenue of $219.06 mln, beating analysts' estimates $204.96 mln - data compiled by LSEG
** As of last close, stock down 10.2% YTD
(Reporting by Anand Gopal in Bengaluru)
Recent news on Supernus Pharmaceuticals
See all newsHuron Consulting poised to hit fresh record ahead of S&P SmallCap addition
Brief: S&P Dow Jones Indices Msg Rangers And Huron Consulting Group Set To Join S&P Smallcap 600
Brief: Supernus Pharmaceuticals Says FDA Grants Seven Years Orphan-Drug Exclusivity For Onapgo
Supernus Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE -Micron Technology, Ares Management, Boeing